Pentara’s clients are primarily small pharmaceutical and biotech companies, but also include academic groups, medium and large pharmaceutical companies. Our projects include phase 1-phase 4 clinical trials. Our phase 1 experience includes single ascending dose (SAD), multiple ascending dose (MAD), pharmacokinetic, bioequivalence, and multi-stage cross-over trials. In phase 2, we provide a strategic balance between cost and sample size by helping our clients reduce error in order to increase the power of the study within a manageable budget. In many cases we can increase the impact of the sample size by 20-30%

Piechart of the percent categories of Pentara's clients

Representative clients:

  • Acumen Pharmaceuticals Inc.
  • Affiris AG
  • Alkahest
  • Allergan
  • Alzheon Inc.
  • Amylyx Pharmaceuticals Inc.
  • Apodemus
  • Avanir Pharmaceuticals, Inc.
  • Banner Alzheimer's Institute
  • Biogen
  • Dr. Richard Isaacson
  • Gerson Lehrman Group
  • Grifols Shared Services North America, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Neurotrope BioScience, Inc.
  • Nutricia Research B.V.
  • PhotoPharmics, Inc.
  • Regenera Pharma LTD
  • Roche (F. Hoffmann-La Roche Ltd - Switzerland)
  • Spaulding Clinical Research
  • Toyama Chemical Co., LTD
  • vTv Therapeutics LLC